Is There A Role for Bivalirudin During PCI in Stable CAD? - Anthony Bavry

↳ This is a section part of Moment: CRT 2017: ACS & AMI Management - ACS Pharmacotherapy

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Is There A Role for Bivalirudin During PCI in Stable CAD? - Anthony Bavry  at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Interventional Fellows
  • Interventional Radiologists
  • Vascular Surgeons
  • Emergency Physicians
  • Physicians with an interest in Cardiovascular Innovations

Learning Objectives

Updates on ACS Pharmacology

Other Components in this Moment

Overview
ACS/PCI Guidelines and AUC Update: What Is New? - Manesh Patel
Is There A Role for Bivalirudin During PCI in Stable CAD? - Anthony Bavry
Use of Cangrelor in ACS - Case Presentations - Gary Schaer
Polypharmacy Anticoagulation - AF meets PCI
How Will PIONEER AF-PCI Change Our Practice? - Roxana Mehran
When to Switch and How to Switch Antiplatelet Therapy - Dominick Angiolillo
The Use of IIb/IIIa Inhibitors in ACS Patients - Michael Lipinski
NOACS for ACS: Is There a Role? - Roxana Mehran
Monotherapy for Stable Patients the Way to Go (Global Freedom) - Patrick Serruys
Updated North American Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI - Dominick Angiolillo
Monotherapy After 3 Months TWILIGHT (update) - Usman Baber
Is There a Role for Antiplatelet or Genetic Testing to Tailor Antiplatelet Therapy in 2017? - Paul Gurbel
Loading Simple Education